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Background: Hypertension has been associated to diabetes, and participates in the development of diabetic
complications. The spontaneously hypertensive rat (SHR) is the gold standard model for the study of hypertension,
and experimental diabetes has been currently investigated in SHR. Wistar-Kyoto rat is usually taken as control for
SHR, however, regarding the glycemic homeostasis, WKY may be similar to SHR, when compared to the standard
Wistar rat, importantly affecting the interpretation of data. Slc2a4 gene, which encodes the GLUT4 protein, is
expressed in insulin-sensitive tissues, such as muscle cells and adipocytes, and alteration in Slc2a4/GLUT4 expression
is inversely related to glycemic levels. We investigated the effect of diabetes on the expression of Slc2a4/GLUT4 and
glycemic control in Wistar-Kyoto and SHR.
Findings: Slc2a4 mRNA (Northern-blotting) and GLUT4 protein (Western-blotting) were investigated in skeletal
muscles (soleus and extensor digitorum longus) of Wistar, Wistar-Kyoto and SHR, rendered or not diabetic for
1 month. Non-diabetic SHR shows hyperinsulinemia, and unaltered GLUT4 expression. The hyperglycemia was
significantly attenuated in diabetic Wistar-Kyoto and SHR, compared to that observed in diabetic Wistar, although
all of them presented the same hypoinsulinemic levels. Besides, diabetes significantly reduced Slc2a4/GLUT4 in
Wistar, as expected; however, that was not observed in diabetic Wistar-Kyoto and SHR.
Conclusions: Non-diabetic SHR is insulin resistant, despite unaltered GLUT4 expression. Diabetic Wistar-Kyoto and
diabetic SHR presented high Slc2a4/GLUT4 expression in skeletal muscle, as compared to diabetic Wistar. This
Slc2a4/GLUT4 regulation does not depend on insulin level and possibly protects the WKY and SHR from severe
glycemic impairment.
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The spontaneously hypertensive rat (SHR) strain was de-
veloped by Okamoto and Aoki [1], and it is the most
studied animal model for human essential hypertension.
As a result of selection for increased blood pressure
prone Wistar-Kyoto rats [1], researchers usually take the
normotensive Wistar-Kyoto rats (WKY) as the controls
for SHR. In this context, although the Wistar-Kyoto rats
are normotensive, some of their features may alter due* Correspondence: abarbara@icb.usp.br
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article, unless otherwise stated.to biological variability [2], besides being different from
the standard Wistar rat [3,4].
The glucose transporter GLUT4, encoded by the sol-
ute carrier 2A4 (Slc2a4) gene, is the insulin-regulatable
glucose transporter, and confers to the skeletal muscle
and adipose tissue a fundamental role in the glycemic
homeostasis [5]. As compared to Wistar rats, WKY
and SHR are glucose intolerant, and show some age-
dependent changes in Slc2a4 mRNA and GLUT4 pro-
tein in gastrocnemius and heart [3,6].
The association of hypertension and diabetes has been
highlighted since the advent of the metabolic syndrome [7].
Besides, in the development of diabetic complications suchentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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factor associated [8]. Thus, the association of experimental
diabetes and hypertension has been currently investigated
in SHR [9-12]; meanwhile, the choice of the control animal
is still controversial.
Considering the above, the present study investigated
the effect of diabetes on Slc2a4 and GLUT4 expression
in skeletal muscles, as well on the glycemic homeostasis
of Wistar, Wistar-Kyoto and SHR.Methods
Animals
Twelve-week old male Wistar rats (W), Wistar-Kyoto
rats (WKY) and spontaneously hypertensive rats (SHR)
from the Animal Center of the Institute of Biomedical
Sciences, University of Sao Paulo (Sao Paulo, Brazil),
were rendered diabetic by alloxan injection (40 mg/kg
body-weight), as previously described [10,11]. After 4 weeks
of diabetes induction, the following groups were investi-
gated: non-diabetic Wistar (W), diabetic-Wistar (D-W),
non-diabetic Wistar-Kyoto (WKY), diabetic Wistar-Kyoto
(D-WKY), non-diabetic SHR (SHR) and diabetic SHR
(D-SHR). The experimental protocol (#015/2008) was
approved by the Ethical Committee for Animal Research of
the Institute of Biomedical Sciences, University of Sao
Paulo.Blood and urine collection and analysis
Twenty-four hour urine was collected immediately before
the experiment (8:00–10:00 AM, without food restriction).
The animals were anesthetized (sodium pentobarbital,
40 mg/kg body weight, i.p.) and blood samples were
collected for analysis. Blood glucose concentration was
measured by a glucometer (Precision QID, MediSense,
Sao Paulo, SP, Brazil), urinary glucose concentration by
the enzymatic-colorimetric method (Glicose Enzimatica,
ANALISA Diagnostica, Belo Horizonte, BR), and plasma
insulin by radioimunoassay (Coat-a-Count Insulin DPC,
Los Angeles, CA, USA).Table 1 General characteristics of the animals
W D-W W
Body weight, g 341 ± 12 259 ± 7*** 28
Soleus weight, g 0.12 ± 0.007 0.11 ± 0.004 0.1
EDL weight, g 0.16 ± 0.01 0.10 ± 0.009** 0.1
Plasma glucose, mg/dl 136 ± 11 517 ± 29*** 13
Plasma insulin, μU/ml 39 ± 5.5 10 ± 2.8** 33
Urinary volume, ml 5.0 ± 0.8 169 ± 36*** 1.7
Urinary glucose, mg/24hs 0.93 ± 0.08 340 ± 13*** 0.1
Morphometric and metabolic parameters were collected from Wistar (W), diabetic W
diabetic SHR (D-SHR). Data are mean ± SEM of 5 to 7 animals. *P < 0.05, **P < 0.01, *
SHR; §§§P < 0.001 vs. D-W. One-way ANOVA, Student Newman Keuls (SNK) post hocTissue collection and analysis
Soleus and extensor digitorum longus (EDL) muscles
were harvested, and immediately processed for analysis
of Slc2a4 mRNA (Northern blotting) and GLUT4 protein
(Western blotting), as previously described [13,14]. The
loading control was performed by beta actin mRNA
hybridization in Northern, and by the coomassie-brilliant-
blue-stained gel in Western [15].
Data analysis
All values were reported as mean ± SEM. The compari-
sons were performed by one-way ANOVA, with Student
Newman Keuls (SNK) as the post hoc test.
Results
Table 1 shows the general characteristics of the rats. The
body weight of non-diabetic SHR and WKY was smaller
(P < 0.001 vs. W); however, the weights of both soleus
and EDL muscles were similar among the groups. D-W
and D-WKY had decreased body weight (P < 0.001 and
P < 0.05, respectively) while in D-SHR body weight was
unchanged, as compared to their respective controls.
Only the EDL weight of W rats was reduced by diabetes.
SHR plasma insulin was the highest; however, diabetes
reduced the plasma insulin to similar values in all
groups. Curiously, the degree of glycemic imbalance was
much more severe in D-W than in D-SHR or D-WKY,
considering the significantly (P < 0.001) higher values of
glycemia, urinary volume and glucose excretion.
Concerning Slc2a4/GLUT4 expression, WKY and SHR
showed higher Slc2a4 mRNA content in soleus, as com-
pared to W (P < 0.05, Figure 1A); however, the GLUT4
expression did not alter (Figure 1B). In EDL, Slc2a4
mRNA was highest in SHR (P < 0.05 vs. W and WKY,
Figure 1C), but again this difference did not reflect in
GLUT4 expression (Figure 1D).
As expected, diabetes reduced (P < 0.05 to P < 0.001)
Slc2a4 mRNA and GLUT4 protein expression in soleus
(Figure 1A and B) and EDL (Figure 1C and D) of D-W
rats. On the other hand, diabetes did not affect Slc2a4KY D-WKY SHR D-SHR
8 ± 8*** 234 ± 15+ 264 ± 8*** 253 ± 12
1 ± 0.006 0.11 ± 0.003 0.11 ± 0.005 0.11 ± 0.006
4 ± 0.01 0.14 ± 0.006 0.13 ± 0.008 0.12 ± 0.01
0 ± 4 239 ± 6+++§§§ 149 ± 15 238 ± 10°°°§§§
± 3.7 11 ± 2.7++ 56 ± 8.6*++ 9 ± 2.3°°°
± 0.4 46 ± 7§§§ 5.5 ± 0.7 52 ± 6§§§
8 ± 0.06 121 ± 22+++§§§ 1.17 ± 0.5 126 ± 9°°°§§§
istar (D-W), Wistar-Kyoto (WKY), diabetic Wistar-Kyoto (D-WKY), SHR (SHR) and
**P < 0.001 vs. W; +P < 0.05, ++P < 0.01, +++P < 0.001 vs. WKY; °°°P < 0.001 vs.
test.
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rats. Similarly GLUT4 protein was unchanged in soleus
of D-SHR (Figure 1B), but it decreased in EDL of
D-SHR (P < 0.001 vs. SHR, Figure 1D). Importantly, the
GLUT4 protein was significantly higher in D-WKY and
D-SHR as compared to D-W, in both soleus and EDL.Discussion
Previous studies have proposed that WKY and SHR are
insulin resistant, both presenting age-dependent alter-
ations in glycemia and in the insulin response to a glu-
cose loading [3]. Our results show SHR maintained
the same basal glycemia at the expense of a significant
hyperinsulinemia, a profile consistent with decreased in-
sulin sensitivity; however, no differences in plasma glu-
cose and insulin levels were found between WKY and W
rats, suggesting they are equally sensitive to insulin.
Interestingly, WKY and SHR had a ~15% reduced body
weight, as compared to the W rats. This reduction must
be a consequence of reduced fat mass, considering the
unaltered lean mass, which can be assumed by the simi-
lar soleus and EDL weights among the groups. In both
humans and mice, weight loss has been associated
with increased insulin sensitivity [16]; nevertheless, the
present detection that leaner SHR are insulin resistant
suggests that mechanisms other than the fat mass are
regulating insulin sensitivity.
Alloxan treatment renders animals diabetic with no
complete destruction of beta cell [17-19]; thus, as ex-
pected, the present diabetic groups were all hypoinsuli-
nemic. D-W rats had a severe body weight loss, as
compared to D-WKY and D-SHR, what suggests some
degree of protection against diabetes-induced weight
loss in WKY and SHR. Surprisingly, the glycemic de-
rangement was much worse in D-W than in D-WKY
and D-SHR, and that was not related to a different de-
gree of beta cells destruction, since basal insulinemia
was similar among the diabetic groups. Thus, WKY and
SHR seem to be somewhat protected against the diabetic
injuries.
GLUT4 protein plays a key role in the insulin-induced
glucose disposal, which is mainly performed in skeletal
muscle [20]. Here in, GLUT4 expression in both soleus
and EDL was unchanged among the groups. So, the
insulin resistance of SHR cannot be attributed to decreased
GLUT4 expression as usually observed; remaining a defect
in the GLUT4 translocation as a probable cause of the re-
duced muscle glucose disposal. In fact impaired IRS/PI3K/
Akt activation [21] in skeletal muscle and GLUT4 trans-
location in adipose tissue [22] have already been described
in SHR. Curiously the Slc2a4 mRNA was increased in so-
leus from WKY and SHR and in EDL from SHR as well,
despite the unchanged GLUT4 protein, pointing out aposttranscriptional regulation of this gene. During fast-
ing, enhancing effect of beta-adrenergic activity on
Slc2a4 mRNA expression in soleus and EDL rat mus-
cles has been suggested [14]. Since increased beta-
adrenergic activity is characteristic of SHR [23], this
could explain the increased Slc2a4 expression observed
in these rats. Nevertheless, it is difficult to explain the
similar regulation observed in WKY, since there is no
clear report comparing peripheral sympathetic activity
of WKY and Wistar rats.
Diabetes decreases Slc2a4 and GLUT4 expression in
soleus, EDL and gastrocnemius muscles, as well as in
white adipose tissue [19,24], and that was presently con-
firmed in both muscles from D-W. However, that is far
from the observed in WKY and SHR, in which diabetes
reduced GLUT4 protein only in EDL from SHR; even
so, the protein content remained much higher in D-SHR
than in D-W. This may hold the key explanation for the
glycemic values observed in D-WKY and D-SHR: the in-
creased GLUT4 content in skeletal muscle improves
insulin-induced glucose disposal, and this allows similar
insulinemic levels to achieve glycemic levels ~50% lower
than those observed in D-W.
It has been proposed that the diabetes effect on redu-
cing Slc2a4/GLUT4 expression is caused by the hypergly-
cemia per se, since the glycemia reduction by phlorizin
restored the GLUT4 expression in diabetic rats [25].
Therefore, it is possible that Slc2a4 and GLUT4 expres-
sion are much more affected in D-W rats than in D-WKY
and D-SHR because of their severe hyperglycemia. Con-
versely, increased GLUT4 expression decreases glycemia
[5], and D-WKY and D-SHR showed much more GLUT4.
Thus, both mechanisms seems to establish a virtuous cir-
cle, in which decreased glycemia enhances GLUT4, and
increased GLUT4 decreases glycemia, leading to an im-
proved glycemic homeostasis.
As highlighted above, discrepancy between changes in
Slc2a4 mRNA and GLUT4 protein implies posttran-
scriptional regulation, and this is somewhat common for
the Slc2a4 gene. Our group has found discrepancies be-
tween Slc2a4 mRNA and GLUT4 protein in skeletal
muscles, with variations in the Slc2a4 mRNA poly(A)
tail length, explaining the altered translation efficiency
[13,14]. Here, discrepancies were detected independently
of increase or decrease of the Slc2a4 mRNA, and the
data suggest that both WKY and SHR need more mRNA
transcripts to maintain proper GLUT4 level.
Finally, we point out that WKY and SHR similarly
regulate some metabolic-related parameters, such as
body weight, diabetes-induced impairment of glycemia
and Slc2a4/GLUT4 regulations, all of them different
from W rats. This feature can disable WKY as a good
control for SHR, at least in studies focusing on glucose




















































































Figure 1 Slc2a4 and GLUT4 expression in skeletal muscle. Rats were injected with either vehicle (Wistar, W; Wistar-Kyoto, WKY and Spontaneously
Hypertensive Rats, SHR) or alloxan (diabetic Wistar, D-W; diabetic Wistar-Kyoto, D-WKY and diabetic SHR, D-SHR), and studied after 4 weeks, without
any treatment. Skeletal muscles were excised for analysis of soleus Slc2a4 mRNA (A) and GLUT4 protein (B) expression and EDL Slc2a4 mRNA (C) and
GLUT4 protein (D) expression. Data are mean ± SEM of 5 to 7 animals. #P < 0.05, ##P < 0.01, ###P < 0.001 vs. other groups, *P < 0.05 vs.
W, + P < 0.05 vs. WKY, ◊◊P < 0.01 vs. D-WKY, ○P < 0.05, ○○○P < 0.001 vs. SHR. One-way ANOVA, SNK post hoc test.
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diastolic stiffness, WKY rats were much closer to SHR
than to W rats [4].Conclusion
Concluding, the present study reveals that, although the
insulin resistance was observed only in SHR, both WKY
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duced body weight and increased Slc2a4/GLUT4 expres-
sion in skeletal muscles. Furthermore, diabetes induction
promoted a much smaller impairment of glycemic
homeostasis in WKY and SHR, and this was not related
to different reduction in plasma insulin concentration.
Importantly, diabetes did not reduce Slc2a4/GLUT4 ex-
pression in muscles, as expected. In summary, when
compared to W rats, both WKY and SHR are similarly
protected against severe hyperglycemia, through a path-
way unrelated to commitment of insulin secretion, but
apparently involving absence of suppression of Slc2a4/
GLUT4 expression.
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